Clinical trials: Genital Neoplasm, Female
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Uterine Fibroids (UF)
A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Uterine Fibroids (UF) are benign smooth muscle neoplasms of the uterus that affect women of reproductive age. UFs are one of the leading causes of hospitalizations for gynecological disorders and often lead to hysterectomy.
- Trial name
- Pink Orchid (NCT06058728)
- Where
- United States
- Sponsor
- AbbVie
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Infections, Papillomavirus, Papillomavirus Vaccines
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00359619
- Testing
- CervarixTM, HPV investigational vaccine GSK568893A, different formulations
- Where
- 10 sites in United States, Belgium
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
Prostate Cancer, mCRPC
A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
Primary Efficacy Endpoint Radiographic Progression-Free Survival (rPFS): rPFS is defined as the time from randomization to radiographic disease progression (PD), as assessed by Blinded Independent Central Review (BICR) according…
- Trial name
- NCT07853209
- Testing
- [177-Lu]Ludotadipep, Best supportive care/standard of care (BSC/SOC) alone
- Where
- 8 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- FutureChem
Advanced Solid Tumor, Recurrent Endometrial Cancer
Study of ART0380 in Patients With Biologically Selected Solid Tumors
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein…
- Conditions
- Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
- Trial name
- ARTIST (NCT05798611)
- Testing
- ART0380
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Artios Pharma Ltd
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Ovarian Epithelial Cancer, Fallopian Tube Cancer
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02435186
- Testing
- p53 gene, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Endometrial Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.
- Trial name
- NCT05797831
- Testing
- Navtemadlin
- Where
- 83 sites in United States, Austria and 15 more
- Volunteers
- 268 people
- Sponsor
- Kartos Therapeutics, Inc.
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Cancer of Endometrium, Cancer of Cervix
Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients
Pain relief following laparotomy surgery requires a variety of techniques including invasive ones like epidural or nerve blocks along with different classes of drugs, out of which opioids are most predominant.
- Trial name
- NCT05742711
- Testing
- Primary Relief
- Where
- India
- Volunteers
- 48 people
- Sponsor
- DyAnsys, Inc.
Cervical Cancer
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
- Trial name
- NCT07080216
- Testing
- ZG005, Gecacitinib, Bevacizumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Tumors, Ovarian Cancer
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT02367352
- Testing
- Alisertib, Paclitaxel
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.